Table 1. Baseline demographic and clinical characteristics of six critically ill COVID-19 patients from the Third People’s Hospital of Shenzhen, China.
| Number of patients | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 |
|---|---|---|---|---|---|---|
| Patient characteristics | ||||||
| Sex | M | M | F | M | M | M |
| Age, years | 66 | 63 | 60 | 59 | 69 | 64 |
| Exposure to Hubei Province | Y | Y | Y | N | N | Y |
| Concomitant chronic diseases | Hypertension | Sleep apnea syndrome; COPD | Diabetes | Hypertension | Hypertension | Aortic sclerosis |
| Initial symptoms | Fever; 39 °C; cough | Fever; 38.4 °C; cough; chest soreness/dyspnea | Fever; 39.6 °C | Fever; 39.7 °C; abdominal pain/nausea; fatigue | Fever; 38.6 °C; cough; muscle ache | Fever; 39 °C; cough; sore throat |
| Clinical outcome | Died | Died | Discharged | Died | Remained in hospital | Discharged |
| Number of days in the hospital | 36 | 32 | 53 | 59 | 57 | 55 |
| Complications prior to Tocilizumab used | ||||||
| ARDS | Severe | Severe | Mild | Mild | Mild | Mild |
| Bacterial and/or fungal infection | Y | Y | Y | Y | Y | Y |
| Septic shock | Y | Y | N | N | N | N |
| Myocardial injury | Y | N | N | Y | Y | N |
| Liver function damage | Y | N | N | N | N | N |
| Renal damage | Y | N | N | Y | N | N |
| Coagulation dysfunction | Y | Y | Y | Y | N | N |
| Tocilizumab used (mg) | 320 | 320 | First: 320; second: 240 | First: 320; second: 640 | 320 | 320 |
| Interval between onset of symptom and mechanical ventilation used, days | 19 | 17 | 9 | 18 | 12 | 25 |
| Interval between onset of symptom and Tocilizumab used, days | 40 | 35 | 26 | 30 | 13 | 27 |
M, male; F, female; Y, yes; N, no; mg, milligrams; C, celsius; COPD, chronic obstructive pulmonary disease; ARDS, acute respiratory distress syndrome.